Ghermes G. Chilov

47 Leninsky Avenue
Moscow, MOW 119991, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Journal: Annals of hematology

Published: October 27, 2024

Author Correction: Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.

Author Correction: Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.

Journal: Scientific reports

Published: October 11, 2022

A New Class of Uracil-DNA Glycosylase Inhibitors Active against Human and Vaccinia Virus Enzyme.

A New Class of Uracil-DNA Glycosylase Inhibitors Active against Human and Vaccinia Virus Enzyme.

Journal: Molecules (Basel, Switzerland)

Published: September 14, 2021

Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.

Inhibition of SYK and cSrc kinases can protect bone and cartilage in preclinical models of osteoarthritis and rheumatoid arthritis.

Journal: Scientific reports

Published: April 05, 2021

Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.

Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.

Journal: European journal of medicinal chemistry

Published: March 19, 2020

The role of human in the loop: lessons from D3R challenge 4.

The role of human in the loop: lessons from D3R challenge 4.

Journal: Journal of computer-aided molecular design

Published: June 14, 2019

PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells.

PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells.

Journal: International journal of oncology

Published: December 03, 2018

Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.

Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.

Journal: Leukemia & lymphoma

Published: July 14, 2017

Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review.

Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review.

Journal: Mediterranean journal of hematology and infectious diseases

Published: February 10, 2017

An explicit account of solvation is essential for modeling Suzuki-Miyaura coupling in protic solvents.

An explicit account of solvation is essential for modeling Suzuki-Miyaura coupling in protic solvents.

Journal: Dalton transactions (Cambridge, England : 2003)

Published: September 25, 2015

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Journal: Leukemia

Published: July 16, 2014

2,3-Dihydroxy-quinoxaline induces ATPase activity of Herpes Simplex Virus thymidine kinase.

2,3-Dihydroxy-quinoxaline induces ATPase activity of Herpes Simplex Virus thymidine kinase.

Journal: FEBS letters

Published: November 28, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026